

**STATISTICAL COMPENDIUM:
MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2001
ALASKA**

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

SUPPLEMENTAL TABLES

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	No. of Benes							No. of Bene Mos						
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown		
All	107,802	577	6,867	23,981	76,351	26	900,492	5,735	69,806	168,669	656,177	105		
Age														
5 and younger	29,155	0	356	0	28,799	0	241,668	0	3,267	0	238,401	0		
6-14	35,083	0	717	4	34,362	0	317,107	0	7,844	24	309,239	0		
15-20	16,362	0	562	2,743	13,055	2	131,794	0	5,703	18,206	107,880	5		
21-44	21,357	0	2,369	18,840	135	13	156,009	0	24,452	130,851	657	49		
45-64	5,202	8	2,796	2,387	0	11	47,477	71	27,824	19,531	0	51		
65-74	397	326	65	6	0	0	4,102	3,346	701	55	0	0		
75-84	189	188	1	0	0	0	1,840	1,837	3	0	0	0		
85 and older	56	55	1	0	0	0	493	481	12	0	0	0		
Unknown	1	0	0	1	0	2	0	0	0	2	0	0		
Gender														
Female	59,691	370	3,549	18,475	37,271	26	490,777	3,757	36,660	128,805	321,450	105		
Male	48,108	207	3,318	5,506	39,077	0	409,693	1,978	33,146	39,864	334,705	0		
Unknown	3	0	0	0	3	0	22	0	0	0	22	0		
Race														
White	45,413	108	3,711	10,956	30,614	24	376,191	1,014	37,828	75,942	261,310	97		
African American	5,743	6	425	1,234	4,078	0	49,203	53	4,239	9,063	35,848	0		
Other/unknown	56,646	463	2,731	11,791	41,659	2	475,098	4,668	27,739	83,664	359,019	8		
Use of Nursing Facilities^c														
Entire year	89	20	68	0	1	0	816	187	627	0	2	0		
Part year	67	10	57	0	0	0	646	84	562	0	0	0		
None	107,646	547	6,742	23,981	76,350	26	899,030	5,464	68,617	168,669	656,175	105		
Maintenance Assistance Status														
Cash	42,954	550	6,278	15,844	20,282	0	373,981	5,521	63,748	123,076	181,636	0		
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0		
Poverty-related	56,885	0	0	6,310	50,549	26	456,397	0	0	31,642	424,650	105		
Other/unknown	7,963	27	589	1,827	5,520	0	70,114	214	6,058	13,951	49,891	0		
Managed Care Status														
FFS all year	107,802	577	6,867	23,981	76,351	26	900,492	5,735	69,806	168,669	656,177	105		
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0		
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0		

Table ND2

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	% with at Least One Rx	Mean No. of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Services	Rx \$ as % of All Services	No. of Benes
All	52.2 %	5.5	\$346	\$63	\$4,103	8.4 %	107,802
Age							
5 and younger	52.0	2.1	85	40	3,006	2.8	29,155
6-14	41.6	2.3	179	79	2,674	6.7	35,083
15-20	49.8	3.4	225	66	4,945	4.6	16,362
21-44	65.1	10.1	638	63	5,394	11.8	21,357
45-64	76.1	31.9	2,006	63	10,806	18.6	5,202
65-74	79.8	27.2	1,217	45	13,696	8.9	397
75-84	74.1	23.4	1,112	48	10,598	10.5	189
85 and older	71.4	30.6	1,404	46	20,110	7.0	56
Unknown	0.0	0.0	0	0	562	0.0	1
Basis of Eligibility^c							
Aged	77.1	26.7	1,221	46	12,783	9.6	577
Disabled	80.9	35.7	2,810	79	20,813	13.5	6,867
Adults	62.7	7.0	366	52	3,684	9.9	23,981
Children	46.1	2.2	111	51	2,664	4.2	76,351
Unknown	57.7	8.7	1,869	214	10,017	18.7	26
Gender							
Female	55.7	6.5	364	56	4,105	8.9	59,691
Male	47.8	4.3	324	75	4,101	7.9	48,108
Unknown	0.0	0.0	0	0	3,674	0.0	3
Race							
White	59.4	7.5	495	66	4,354	11.4	45,413
African American	56.7	6.0	335	56	3,366	9.9	5,743
Other/unknown	45.9	3.9	228	59	3,977	5.7	56,646
Use of Nursing Facilities^d							
Entire year	93.3	60.5	4,302	71	99,852	4.3	89
Part year	95.5	81.1	5,082	63	81,632	6.2	67
None	52.1	5.4	340	63	3,976	8.5	107,646
Maintenance Assistance Status							
Cash	58.3	10.0	654	66	5,279	12.4	42,954
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	46.7	2.1	107	51	2,613	4.1	56,885
Other/unknown	58.3	6.2	392	63	8,406	4.7	7,963

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	Mean No. of Rx	Mean Rx \$	Rx \$ as % of All Services	No. of Rx, % with:					Mean \$, All Services	Benes	Bene Mos	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less				
All	0.7	\$41	8.4 %	47.8 %	42.9 %	3.9 %	3.5 %	1.4 %	0.5 %	\$491	107,802	900,492
Age												
5 and younger	0.3	10	2.8	48.0	49.8	1.7	0.4	0.0	0.0	363	29,155	241,668
6-14	0.3	20	6.7	58.4	38.2	1.9	1.2	0.2	0.0	296	35,083	317,107
15-20	0.4	28	4.6	50.2	43.2	4.0	2.3	0.3	0.1	614	16,362	131,794
21-44	1.4	87	11.8	34.9	44.7	8.1	7.8	3.4	1.1	738	21,357	156,009
45-64	3.5	220	18.6	23.9	28.0	10.8	19.3	12.0	6.0	1,184	5,202	47,477
65-74	2.6	118	8.9	20.2	32.5	12.6	20.7	11.3	2.8	1,326	397	4,102
75-84	2.4	114	10.5	25.9	29.1	13.2	21.7	7.9	2.1	1,089	189	1,840
85 and older	3.5	159	7.0	28.6	19.6	7.1	23.2	19.6	1.8	2,284	56	493
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	281	1	2
Basis of Eligibility^c												
Aged	2.7	123	9.6	22.9	29.5	12.5	21.7	10.7	2.8	1,286	577	5,735
Disabled	3.5	276	13.5	19.1	29.9	11.3	20.8	12.2	6.6	2,047	6,867	69,806
Adults	1.0	52	9.9	37.3	46.0	7.6	6.4	2.3	0.4	524	23,981	168,669
Children	0.3	13	4.2	53.9	43.1	2.0	0.9	0.1	0.0	310	76,351	656,177
Unknown	2.2	463	18.7	42.3	19.2	3.8	26.9	7.7	0.0	2,480	26	105
Gender												
Female	0.8	44	8.9	44.3	44.6	4.4	4.0	1.9	0.7	499	59,691	490,777
Male	0.5	38	7.9	52.2	40.7	3.2	2.8	0.9	0.3	482	48,108	409,693
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	501	3	22
Race												
White	0.9	60	11.4	40.6	46.5	5.1	4.7	2.2	0.8	526	45,413	376,191
African American	0.7	39	9.9	43.3	47.0	4.4	3.3	1.4	0.5	393	5,743	49,203
Other/unknown	0.5	27	5.7	54.1	39.5	2.9	2.5	0.8	0.3	474	56,646	475,098
Use of Nursing Facilities^d												
Entire year	6.6	469	4.3	6.7	5.6	6.7	23.6	40.4	16.9	10,891	89	816
Part year	8.4	527	6.2	4.5	6.0	11.9	28.4	26.9	22.4	8,467	67	646
None	0.7	41	8.5	47.9	42.9	3.9	3.4	1.4	0.5	476	107,646	899,030
Maintenance Assistance Status												
Cash	1.1	75	12.4	41.7	41.8	5.4	6.6	3.2	1.3	606	42,954	373,981
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.3	13	4.1	53.3	43.4	2.3	0.9	0.1	0.0	326	56,885	456,397
Other/unknown	0.7	45	4.7	41.7	45.1	6.5	5.0	1.4	0.3	955	7,963	70,114

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	All Rx		Patented Brand-Name Drugs		Off-Patent Brand-Name Drugs		Generic Drugs	
	No. of Rx	Rx \$	No. of Rx	\$ per Rx	No. of Rx	Rx \$	No. of Rx	Rx \$
All	0.7	\$41	0.3	\$63	0.1	\$3	0.3	\$19
Age								
5 and younger	0.3	10	0.1	40	0.0	0	0.1	2
6-14	0.3	20	0.1	79	0.0	1	0.1	2
15-20	0.4	28	0.2	66	0.0	2	0.2	4
21-44	1.4	87	0.6	63	0.1	7	0.7	12
45-64	3.5	220	1.7	63	0.3	18	1.4	30
65-74	2.6	118	1.2	45	0.3	11	1.1	20
75-84	2.4	114	1.1	48	0.2	9	1.1	20
85 and older	3.5	159	1.8	46	0.4	8	1.3	28
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
Basis of Eligibility^d								
Aged	2.7	123	1.3	46	0.3	11	1.1	21
Disabled	3.5	276	1.8	79	0.3	21	1.4	30
Adults	1.0	52	0.4	52	0.1	4	0.5	9
Children	0.3	13	0.1	51	0.0	1	0.1	2
Unknown	2.2	463	0.8	214	0.1	5	1.2	24
Gender								
Female	0.8	44	0.4	56	0.1	4	0.4	7
Male	0.5	38	0.2	75	0.0	2	0.2	5
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
Race								
White	0.9	60	0.4	66	0.1	4	0.4	8
African American	0.7	39	0.4	56	0.0	2	0.3	5
Other/unknown	0.5	27	0.2	59	0.0	2	0.2	4
Use of Nursing Facilities^e								
Entire year	6.6	469	2.7	71	0.7	54	3.1	110
Part year	8.4	527	3.9	63	0.8	30	3.7	88
None	0.7	41	0.3	63	0.1	3	0.3	6
Maintenance Assistance								
Status								
Cash	1.1	75	0.5	66	0.1	6	0.5	10
Medically needy	0.0	0	0.0	0	0.0	0	0.0	0
Poverty related	0.3	13	0.1	51	0.0	1	0.1	2
Other/unknown	0.7	45	0.3	63	0.1	4	0.3	6

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 4.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Total No. of Rx	Total Rx \$	No.	As % of All Benes	No. of Bene Mos			
	Total	Patented	Off-Patent	Generic	Total	Patented	Off-Patent	Generic	Total						Patented	Off-Patent	Generic
Anti-infective Agents	0.2	0.1	0.0	0.1	\$12	\$10	\$0	\$2	\$50	\$78	\$97	\$15	79,233	\$3,964,058	34,843	32.3%	336,552
Biologicals	0.3	0.3	0.0	0.0	327	327	0	0	1235	1,239	0	238	520	642,021	221	0.2	1,962
Antineoplastic Agents	0.5	0.2	0.2	0.2	158	137	14	7	296	596	91	48	1,556	460,689	281	0.3	2,918
Endocrine/Metabolic Drugs	0.5	0.3	0.1	0.1	21	15	3	2	39	53	32	18	47,230	1,862,446	9,473	8.8	89,336
Cardiovascular Agents	1.2	0.5	0.1	0.6	43	29	3	10	37	60	35	17	53,234	1,956,266	4,564	4.2	45,826
Respiratory Agents	0.4	0.2	0.0	0.1	19	15	0	3	50	70	39	22	54,710	2,755,694	15,155	14.1	147,975
Gastrointestinal Agents	0.5	0.3	0.0	0.2	50	43	4	4	100	136	134	24	27,690	2,775,383	5,603	5.2	55,414
Genitourinary Agents	0.2	0.2	0.0	0.1	10	9	0	1	42	52	44	16	6,966	293,362	2,995	2.8	27,987
CNS Drugs	1.0	0.5	0.1	0.4	80	63	9	8	81	117	110	22	104,215	8,398,070	10,804	10.0	105,184
Stimulants/Anti-obesity/Anorexia	0.6	0.3	0.1	0.2	36	25	3	8	58	77	48	35	15,895	929,315	2,502	2.3	25,631
Miscellaneous Psychological/Neurological Agents	0.6	0.5	0.1	0.1	97	94	1	2	156	198	15	24	422	65,965	63	0.1	681
Analgesics and Anesthetics	0.5	0.2	0.0	0.3	34	26	3	6	63	164	58	18	93,850	5,950,505	18,616	17.3	175,251
Neuromuscular Agents	0.7	0.3	0.1	0.3	42	32	3	7	56	97	40	21	48,054	2,712,244	6,413	5.9	64,192
Nutritional Products	0.3	0.0	0.0	0.2	4	0	1	3	14	23	21	12	15,308	207,182	6,131	5.7	54,288
Hematological Agents	0.7	0.2	0.2	0.3	402	394	4	4	558	1,753	21	13	5,205	2,906,838	734	0.7	7,233
Topical Products	0.2	0.1	0.0	0.1	6	4	1	2	31	60	37	17	38,264	1,188,956	19,344	17.9	189,366
Miscellaneous Products	0.5	0.3	0.1	0.2	120	94	16	10	233	333	300	55	688	160,243	134	0.1	1,337
Unknown Therapeutic Category	0.1	0.0	0.0	0.0	3	0	0	0	23	0	0	0	3,236	73,256	2,219	2.1	22,269
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	596,276	37,302,493	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2001. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 4.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Top 10 Drug Groups	Users				Among Users		
	Total Medicaid Rx \$	No. As % of All Benes	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo	
ANTIPSYCHOTICS	\$4,294,713	3,277	34,330	0.8	\$158	\$125	
ANALGESICS - Narcotic	4,291,799	20,250	194,902	18.8	65	22	
ANTIDEPRESSANTS	3,384,294	9,558	95,214	8.9	65	36	
MISC. HEMATOLOGICAL	2,332,937	144	1,509	0.1	1,718	1,546	
ANTICONVULSANT	2,262,304	3,528	36,835	3.3	75	61	
ULCER DRUGS	1,965,928	5,011	50,511	4.6	94	39	
ANTIASTHMATIC	1,556,443	12,402	123,506	11.5	49	13	
ANALGESICS - ANTI-INFLAMMATORY	1,234,855	10,383	100,922	9.6	52	12	
PENICILLINS	951,109	21,341	211,466	19.8	34	4	
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	929,315	2,732	28,280	2.5	58	33	
Total	23,203,697	88,626	877,475	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE^{a,b,c}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ANALGESICS - Narcotic			
	No. of Rx	Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	297,867	\$23,203,697	3,277	3.0 %	34,330	0.8	\$125	20,250	18.8 %	194,902	0.3	\$22
Female	185,643	12,609,833	1,771	3.0	18,436	0.8	109	14,030	23.5	134,045	0.4	21
Disabled	79,328	6,733,518	888	25.0	9,878	1.1	157	2,644	74.5	29,407	0.5	47
5 and younger	427	27,990	0	0.0	0	0.0	0	5	3.3	59	0.1	1
6-14	2,008	173,757	28	10.8	325	0.7	96	25	9.6	294	0.2	5
15-20	1,564	136,897	31	15.3	338	0.8	126	59	29.2	628	0.1	3
21-44	32,757	2,892,050	460	35.4	5,146	1.0	155	1,124	86.4	12,538	0.5	50
45-64	42,306	3,485,793	369	23.1	4,069	1.2	167	1,411	88.4	15,662	0.5	47
65-74	266	17,031	0	0.0	0	0.0	0	20	51.3	226	0.2	5
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	106,315	5,876,315	883	1.6	8,558	0.4	54	11,386	20.3	104,638	0.3	14
5 and younger	9,336	274,644	4	0.0	41	0.1	13	361	2.6	3,665	0.1	2
6-14	13,476	677,330	162	1.0	1,735	0.4	59	942	5.6	9,675	0.1	2
15-20	13,868	685,464	221	2.6	2,212	0.4	54	2,027	23.6	18,682	0.2	3
21-44	57,595	3,396,437	409	2.7	3,710	0.4	46	7,228	48.4	64,450	0.4	18
45-64	9,004	622,133	60	4.3	567	0.5	60	700	50.7	6,759	0.4	24
65-74	2,128	154,379	18	8.0	195	1.1	171	82	36.6	913	0.2	12
75-84	626	47,840	3	2.6	31	0.5	15	32	27.8	346	0.3	7
85 and older	282	18,088	6	18.2	67	0.2	16	14	42.4	148	0.3	22
Male	112,224	10,593,864	1,506	3.1	15,894	0.8	144	6,220	12.9	60,857	0.3	24
Disabled	47,359	5,901,765	839	25.3	9,099	1.0	188	1,408	42.4	15,056	0.5	57
5 and younger	485	30,765	2	1.0	22	0.2	7	10	4.9	113	0.1	2
6-14	4,539	1,280,120	102	22.3	1,168	0.6	109	40	8.8	464	0.2	4
15-20	3,992	787,769	95	26.4	1,018	0.8	141	76	21.1	833	0.2	11
21-44	18,199	1,968,153	435	40.7	4,652	1.1	218	515	48.2	5,518	0.5	50
45-64	19,928	1,822,377	203	16.9	2,215	1.2	189	756	63.1	8,007	0.6	72
65-74	204	11,676	2	7.7	24	1.1	121	11	42.3	121	0.2	5
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	12	905	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	64,865	4,692,099	667	1.5	6,795	0.6	85	4,812	10.7	45,801	0.2	14
5 and younger	12,451	398,442	12	0.1	135	0.4	83	513	3.4	5,259	0.1	2
6-14	25,998	2,311,398	369	2.1	3,909	0.6	91	1,081	6.2	11,177	0.1	2
15-20	10,784	824,245	200	2.8	1,971	0.6	86	1,252	17.4	11,956	0.2	3
21-44	10,065	698,519	63	1.6	537	0.3	55	1,514	37.5	13,049	0.4	26
45-64	4,317	383,889	12	1.2	137	0.4	42	399	39.0	3,787	0.5	55
65-74	746	35,013	5	4.6	48	0.7	18	29	26.9	309	0.2	8
75-84	395	35,395	4	5.5	42	0.5	104	16	21.9	187	0.2	15
85 and older	109	5,198	2	9.1	16	0.1	5	8	36.4	77	0.3	11
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	ANTIDEPRESSANTS					MISC. HEMATOLOGICAL					ANTICONVULSANT				
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean Rx	Mean No. of	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean Rx	Mean No. of	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean Rx	Mean No. of
All	9,558	8.9 %	95,214	0.6	0.6	144	0.1 %	1,509	0.9	\$1,546	3,528	3.3 %	36,835	0.8	\$61
Female	6,761	11.3	66,592	0.5	0.5	74	0.1	808	0.8	59	2,139	3.6	22,254	0.8	60
Disabled	1,996	56.2	21,955	0.8	0.8	53	1.5	591	0.8	61	1,079	30.4	11,955	1.1	80
5 and younger	1	0.7	12	0.9	0.9	0	0.0	0	0.0	0	13	8.7	139	0.8	88
6-14	35	13.5	397	0.6	0.6	1	0.4	12	0.1	27	83	31.9	956	0.8	90
15-20	49	24.3	533	0.6	0.6	0	0.0	0	0.0	0	64	31.7	716	0.8	64
21-44	870	66.9	9,640	0.8	0.8	9	0.7	103	0.8	87	498	38.3	5,503	1.2	90
45-64	1,035	64.8	11,306	0.9	0.9	42	2.6	465	0.8	58	419	26.2	4,617	1.0	72
65-74	6	15.4	67	0.3	0.3	1	2.6	11	0.3	28	2	5.1	24	0.4	15
75-84	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	4,765	8.5	44,637	0.4	0.4	21	0.0	217	0.9	52	1,060	1.9	10,299	0.5	36
5 and younger	13	0.1	125	0.4	0.4	0	0.0	0	0.0	0	28	0.2	298	0.6	50
6-14	393	2.3	4,105	0.4	0.4	1	0.0	12	0.8	29	160	0.9	1,703	0.5	34
15-20	813	9.5	7,716	0.4	0.4	0	0.0	0	0.0	0	141	1.6	1,315	0.5	35
21-44	3,053	20.4	27,949	0.4	0.4	6	0.0	61	0.3	22	623	4.2	5,934	0.5	35
45-64	438	31.7	4,177	0.5	0.5	6	0.4	56	0.8	85	91	6.6	895	0.5	38
65-74	30	13.4	307	0.5	0.5	4	1.8	48	2.0	81	12	5.4	112	1.1	62
75-84	14	12.2	145	0.5	0.5	2	1.7	16	0.4	39	5	4.3	42	0.6	56
85 and older	11	33.3	113	0.6	0.6	2	6.1	24	0.4	17	0	0.0	0	0.0	0
Male	2,797	5.8	28,622	0.6	0.6	70	0.1	701	1.0	3,260	1,389	2.9	14,581	0.9	63
Disabled	1,037	31.3	11,267	0.7	0.7	46	1.4	479	0.9	2,742	751	22.6	8,262	1.1	79
5 and younger	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	14	6.8	153	0.6	57
6-14	87	19.0	1,003	0.6	0.6	2	0.4	24	4.8	36,749	115	25.2	1,324	0.9	77
15-20	95	26.4	1,041	0.8	0.8	1	0.3	12	4.8	34,220	103	28.6	1,136	1.0	98
21-44	418	39.1	4,534	0.8	0.8	2	0.2	16	0.4	116	304	28.5	3,352	1.2	84
45-64	432	36.0	4,629	0.7	0.7	41	3.4	427	0.6	44	213	17.8	2,273	1.0	66
65-74	5	19.2	60	0.9	0.9	0	0.0	0	0.0	0	2	7.7	24	1.0	29
75-84	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	1,760	3.9	17,355	0.5	0.5	24	0.1	222	1.3	4,379	638	1.4	6,319	0.6	42
5 and younger	30	0.2	300	0.3	0.3	0	0.0	0	0.0	0	30	0.2	286	0.5	21
6-14	723	4.1	7,598	0.5	0.5	3	0.0	36	4.3	21,081	300	1.7	3,159	0.6	41
15-20	507	7.0	4,927	0.5	0.5	2	0.0	13	2.8	13,928	158	2.2	1,506	0.5	41
21-44	373	9.2	3,270	0.3	0.3	5	0.1	45	0.3	416	104	2.6	944	0.5	45
45-64	103	10.1	1,003	0.5	0.5	8	0.8	70	0.4	129	32	3.1	286	0.6	51
65-74	10	9.3	111	0.7	0.7	4	3.7	34	1.0	65	8	7.4	67	2.0	76
75-84	8	11.0	89	0.6	0.6	2	2.7	24	0.9	94	6	8.2	71	0.7	27
85 and older	6	27.3	57	1.1	1.1	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7B

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	ULCER DRUGS				ANTI-ASTHMATIC				ANALGESICS - ANTI-INFLAMMATORY						
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	5,011	4.6 %	50,511	0.4	\$39	12,402	11.5 %	123,506	0.3	\$13	10,383	9.6 %	100,922	0.2	\$12
Female	3,463	5.8	34,885	0.4	40	7,188	12.0	71,503	0.3	13	7,423	12.4	71,820	0.2	13
Disabled	1,192	33.6	13,130	0.6	61	1,521	42.9	16,974	0.4	21	1,432	40.3	15,934	0.4	30
5 and younger	13	8.7	117	0.3	18	55	36.7	602	0.3	16	1	0.7	12	0.1	1
6-14	18	6.9	213	0.5	50	41	15.8	460	0.3	14	7	2.7	83	0.1	7
15-20	23	11.4	253	0.4	40	38	18.8	421	0.2	10	30	14.9	315	0.1	3
21-44	387	29.7	4,322	0.6	54	479	36.8	5,377	0.3	16	563	43.3	6,252	0.4	23
45-64	734	46.0	8,039	0.7	67	885	55.4	9,846	0.4	26	818	51.2	9,128	0.5	36
65-74	17	43.6	186	0.3	30	23	59.0	268	0.3	17	13	33.3	144	0.3	23
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	2,271	4.0	21,755	0.3	27	5,667	10.1	54,529	0.2	10	5,991	10.7	55,886	0.2	8
5 and younger	96	0.7	896	0.2	12	1,412	10.1	13,816	0.2	5	120	0.9	1,200	0.1	2
6-14	169	1.0	1,778	0.2	14	1,187	7.0	12,105	0.2	10	420	2.5	4,255	0.1	3
15-20	330	3.8	3,267	0.2	13	791	9.2	7,534	0.2	11	1,198	13.9	10,988	0.2	4
21-44	1,274	8.5	11,765	0.3	28	1,853	12.4	16,865	0.3	12	3,658	24.5	33,485	0.2	9
45-64	280	20.3	2,704	0.4	38	293	21.2	2,758	0.4	19	483	34.9	4,690	0.3	17
65-74	77	34.4	854	0.6	52	97	43.3	1,105	0.4	23	85	37.9	959	0.4	22
75-84	35	30.4	385	0.6	70	27	23.5	276	0.4	21	19	16.5	222	0.3	25
85 and older	10	30.3	106	0.6	61	7	21.2	70	0.3	15	8	24.2	87	0.7	32
Male	1,548	3.2	15,626	0.4	37	5,214	10.8	52,003	0.3	12	2,960	6.2	29,102	0.2	11
Disabled	646	19.5	6,929	0.6	52	767	23.1	8,339	0.4	25	713	21.5	7,822	0.3	22
5 and younger	21	10.2	205	0.3	19	49	23.8	533	0.4	27	1	0.5	12	0.2	3
6-14	39	8.5	450	0.7	61	123	26.9	1,396	0.4	23	10	2.2	100	0.2	39
15-20	30	8.3	334	0.6	51	64	17.8	726	0.4	21	35	9.7	390	0.1	3
21-44	176	16.5	1,912	0.6	47	123	11.5	1,363	0.2	14	242	22.7	2,693	0.3	19
45-64	376	31.4	3,986	0.6	54	404	33.7	4,273	0.5	29	413	34.4	4,507	0.4	25
65-74	4	15.4	42	0.5	50	3	11.5	36	0.5	17	11	42.3	108	0.4	15
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	1	100.0	12	0.1	7	1	100.0	12	0.9	69
Other Eligibles	902	2.0	8,697	0.3	26	4,447	9.9	43,664	0.2	10	2,247	5.0	21,280	0.2	7
5 and younger	155	1.0	1,406	0.2	11	2,178	14.6	21,069	0.2	7	151	1.0	1,458	0.1	2
6-14	157	0.9	1,692	0.2	19	1,520	8.7	15,447	0.2	11	359	2.1	3,658	0.1	2
15-20	152	2.1	1,527	0.2	17	402	5.6	3,936	0.2	12	694	9.6	6,699	0.1	3
21-44	280	6.9	2,500	0.3	31	198	4.9	1,698	0.3	14	761	18.8	6,636	0.2	10
45-64	119	11.6	1,128	0.4	42	93	9.1	926	0.5	24	242	23.6	2,380	0.2	14
65-74	24	22.2	264	0.4	33	33	30.6	366	0.5	19	27	25.0	295	0.3	14
75-84	13	17.8	156	0.8	99	17	23.3	191	0.3	14	9	12.3	106	0.3	30
85 and older	2	9.1	24	0.3	32	6	27.3	31	0.3	22	4	18.2	48	0.1	8
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7C
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	PENICILLINS				STIMULANTS/ANTI-OBESITY/ANOREXIANTS				Mean Rx \$	Mean No. of Rx	Mean No. of Bene Users among Mos	Users as % of All Benes	No. of Users	No. of Bene Users among Mos	Mean Rx \$	Mean No. of Rx	Mean No. of Bene Users among Mos	Users as % of All Benes	No. of Users	No. of Bene Users among Mos	Mean Rx \$	Mean No. of Rx	Mean No. of Bene Users among Mos	Users as % of All Benes	No. of Users	No. of Bene Users among Mos
	No. of Users	Users as % of All Benes	No. of Bene Users among Mos	Mean Rx \$	Mean No. of Rx	Mean No. of Bene Users among Mos	Users as % of All Benes	No. of Users																		
All	21,341	19.8%	211,466	0.1	\$5	2,732	2.5%	28,280	0.6	\$33	107,802	900,492														
Female	12,017	20.1	118,230	0.1	5	736	1.2	7,624	0.5	31	59,690	490,775														
Disabled	912	25.7	10,274	0.1	6	83	2.3	921	0.6	51	3,549	36,660														
5 and younger	69	46.0	742	0.1	5	0	0.0	0	0.0	0	150	1,388														
6-14	93	35.8	1,096	0.2	7	29	11.2	329	0.7	50	260	2,904														
15-20	48	23.8	553	0.1	4	12	5.9	142	0.3	19	202	2,033														
21-44	347	26.7	3,910	0.1	5	24	1.8	250	0.8	73	1,301	13,657														
45-64	351	22.0	3,939	0.1	6	18	1.1	200	0.6	48	1,597	16,237														
65-74	4	10.3	34	0.1	7	0	0.0	0	0.0	0	39	441														
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0														
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0														
Other Eligibles	11,105	19.8	107,956	0.1	4	653	1.2	6,703	0.5	28	56,141	454,115														
5 and younger	4,196	30.1	41,549	0.1	4	21	0.2	213	0.3	18	13,925	115,507														
6-14	2,766	16.4	28,624	0.1	4	441	2.6	4,602	0.5	26	16,916	152,350														
15-20	1,262	14.7	11,965	0.1	4	100	1.2	1,012	0.4	27	8,599	67,684														
21-44	2,609	17.5	23,035	0.1	5	80	0.5	757	0.5	45	14,947	103,429														
45-64	229	16.6	2,289	0.1	6	11	0.8	119	0.7	49	1,382	11,369														
65-74	27	12.1	307	0.1	5	0	0.0	0	0.0	0	224	2,350														
75-84	12	10.4	142	0.1	5	0	0.0	0	0.0	0	115	1,119														
85 and older	4	12.1	45	0.1	4	0	0.0	0	0.0	0	33	307														
Male	9,324	19.4	93,236	0.1	5	1,996	4.1	20,656	0.6	34	48,108	409,693														
Disabled	619	18.7	6,981	0.1	7	164	4.9	1,831	0.7	49	3,318	33,146														
5 and younger	82	39.8	900	0.1	4	3	1.5	34	0.1	3	206	1,879														
6-14	117	25.6	1,352	0.2	7	99	21.7	1,119	0.7	48	457	4,940														
15-20	71	19.7	795	0.1	11	41	11.4	463	0.7	51	360	3,670														
21-44	152	14.2	1,706	0.1	5	11	1.0	122	0.7	58	1,068	10,795														
45-64	196	16.3	2,216	0.1	8	10	0.8	93	0.9	58	1,199	11,587														
65-74	1	3.8	12	0.3	26	0	0.0	0	0.0	0	26	260														
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	3														
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12														
Other Eligibles	8,705	19.4	86,255	0.1	4	1,832	4.1	18,825	0.6	32	44,790	376,547														
5 and younger	4,752	32.0	46,469	0.1	4	78	0.5	805	0.3	16	14,872	122,882														
6-14	2,696	15.5	27,835	0.1	4	1,453	8.3	15,024	0.6	33	17,449	156,903														
15-20	713	9.9	6,916	0.1	5	282	3.9	2,833	0.5	32	7,201	58,407														
21-44	421	10.4	3,802	0.1	5	17	0.4	147	0.6	38	4,041	28,128														
45-64	97	9.5	927	0.1	7	2	0.2	16	0.9	129	1,024	8,284														
65-74	15	13.9	174	0.2	4	0	0.0	0	0.0	0	108	1,051														
75-84	10	13.7	120	0.1	3	0	0.0	0	0.0	0	73	718														
85 and older	1	4.5	12	0.1	2	0	0.0	0	0.0	0	22	174														
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	24														

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	Rx \$ per Bene Mo	No. of Rx per Bene Mo	No. of All-Year NF Residents	Bene Mos among All-Year NF Residents
All	\$469	6.6	89	816
Age				
0-64	523	6.9	66	582
65-74	365	5.8	14	161
75-84	278	5.5	3	30
85 and older	264	5.6	6	43
Unknown	0	0.0	0	0
Gender				
Female	502	6.7	49	478
Male	423	6.5	40	338
Unknown	0	0.0	0	0
Race				
White	538	7.6	43	360
African American	477	6.7	4	45
Other/unknown	408	5.8	42	411
Basis of Eligibility^c				
Aged	338	5.2	20	187
Disabled	509	7.0	68	627
Adults	0	0.0	0	0
Children	345	10.0	1	2
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2001 Medicaid enrollment. A total of 67 beneficiaries who were in nursing facilities for part of their enrollment and their 646 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users							
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total # of Rx	Total Rx \$	No.	As % of All-Year NF Residents	No. of Bene Mos
Anti-infective Agents	0.4	0.2	0.0	0.2	\$29	\$22	\$2	\$4	\$65	\$97	\$342	\$21	217	\$14,078	49	55.1 %	488
Biologicals	0.1	0.1	0.0	0.0	2	2	0	0	18	18	0	0	1	18	1	1.1	12
Antineoplastic Agents	0.4	0.0	0.3	0.1	17	0	15	2	42	0	48	22	9	382	2	2.2	23
Endocrine/Metabolic Drugs	1.1	0.7	0.1	0.3	65	50	2	13	57	69	22	40	406	23,134	35	39.3	354
Cardiovascular Agents	1.9	1.0	0.1	0.8	83	56	3	25	44	58	23	30	821	35,798	44	49.4	429
Respiratory Agents	0.7	0.3	0.0	0.4	34	18	0	16	48	69	0	36	257	12,395	39	43.8	366
Gastrointestinal Agents	1.3	0.4	0.2	0.6	91	49	23	20	71	118	92	31	612	43,527	49	55.1	476
Genitourinary Agents	0.7	0.4	0.0	0.2	55	41	3	11	84	104	76	49	111	9,282	16	18.0	169
CNS Drugs	2.2	1.3	0.2	0.7	201	145	35	21	93	114	155	32	1,168	108,602	61	68.5	539
Stimulants/Anti-obesity/Anorexia	1.5	0.0	0.0	1.5	39	0	0	39	25	0	0	25	37	928	2	2.2	24
Miscellaneous Psychological/Neurological Agents	1.2	1.2	0.0	0.0	172	172	0	0	144	144	0	0	12	1,723	1	1.1	10
Analgesics and Anesthetics	1.1	0.4	0.2	0.5	103	68	13	22	94	177	73	42	403	37,888	42	47.2	367
Neuromuscular Agents	1.4	0.2	0.1	1.1	82	17	4	61	58	94	42	53	639	36,776	47	52.8	451
Nutritional Products	0.6	0.0	0.1	0.6	12	0	2	9	19	0	41	17	136	2,565	21	23.6	218
Hematological Agents	1.2	0.2	0.5	0.5	173	156	9	8	146	825	18	17	232	33,987	23	25.8	196
Topical Products	0.6	0.2	0.1	0.4	44	34	3	7	69	186	33	19	276	18,928	41	46.1	434
Miscellaneous Products	0.2	0.0	0.0	0.2	16	0	0	16	71	0	0	71	7	499	3	3.4	31
Unknown Therapeutic Category	0.4	0.0	0.0	0.0	25	0	0	0	58	0	0	0	41	2,360	10	11.2	93
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	5,385	382,870	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 67 beneficiaries who were in nursing facilities for part of their enrollment and their 646 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2001. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

In Alaska, 4.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Top 10 Drug Groups in Nursing Facilities	Users				Among Users		
	Total Medicaid Rx \$	No. of Users	As % of All-Year NF Residents	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo
ANTIPSYCHOTICS	\$52,473	34	38.2 %	324	1.0	\$164	\$162
ANTIDEPRESSANTS	41,318	60	67.4	527	1.1	74	78
ULCER DRUGS	34,439	37	41.6	364	1.0	95	95
ANTICOAGULANTS	29,553	11	12.4	105	1.4	200	281
ANTICONVULSANT	27,303	34	38.2	338	0.9	87	81
ANALGESICS - Narcotic	20,462	49	55.1	457	0.6	81	45
DERMATOLOGICAL	16,636	58	65.2	619	0.3	80	27
ANALGESICS - ANTI-INFLAMMATORY	17,175	20	22.5	204	0.7	123	84
ANTIDIABETIC	16,364	34	38.2	342	0.8	61	48
ANTIHYPERTENSIVE	16,956	35	39.3	337	1.0	51	50
Total	272,679	372		3,617	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 67 beneficiaries who were in nursing facilities for part of their enrollment and their 646 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	All Top 10 Drug Groups					ANTIPSYCHOTICS					ANTIDEPRESSANTS				
	No. of Rx	Rx \$	Users as %			Mean Rx \$	No. of Bene Mos among Users	Mean No. of Rx	Users as %	No. of Bene Mos among Users	Mean No. of Rx	Users as %	No. of Bene Mos among Users	Mean No. of Rx	
			No. of Users	Residents	NF										No. of Users
All	2,899	\$272,679	34	38.2 %	324	1.0	162	60	67.4 %	527	1.1	\$78			
Female	1,633	175,164	16	32.7	155	1.0	175	38	77.6	326	1.1	81			
Disabled	1,262	143,177	6	16.2	50	0.8	165	26	70.3	222	1.3	103			
64 or younger	1,243	142,541	6	16.7	50	0.8	165	26	72.2	222	1.3	103			
65-74	19	636	0	0.0	0	0.0	0	0	0.0	0	0.0	0			
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0			
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0			
Other Eligibles	371	31,987	10	83.3	105	1.1	180	12	100.0	104	0.7	36			
64 or younger	16	609	1	100.0	2	0.5	13	3	300.0	6	1.3	19			
65-74	288	27,499	8	100.0	92	1.3	205	7	87.5	80	0.6	36			
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0			
85 and older	67	3,879	1	33.3	11	0.1	2	2	66.7	18	0.9	42			
Male	1,266	97,515	18	45.0	169	0.9	150	22	55.0	201	1.0	74			
Disabled	1,087	86,409	13	41.9	129	1.1	191	15	48.4	138	1.1	84			
64 or younger	834	73,830	12	42.9	117	1.1	203	13	46.4	114	1.0	79			
65-74	253	12,579	1	33.3	12	1.0	75	2	66.7	24	1.7	109			
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0			
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0			
Other Eligibles	179	11,106	5	55.6	40	0.4	18	7	77.8	63	0.7	52			
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0			
65-74	67	4,936	2	100.0	18	0.7	30	1	50.0	12	1.0	77			
75-84	88	4,841	1	33.3	6	0.3	16	3	100.0	30	0.9	62			
85 and older	24	1,329	2	66.7	16	0.1	5	3	100.0	21	0.3	23			
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0			

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 67 beneficiaries who were in nursing facilities for part of their enrollment and their 646 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	ULCER DRUGS						ANTICOAGULANTS						ANTICONVULSANT					
	Users as %			Users as %			Users as %			Users as %			Users as %			Users as %		
	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx
All	37	41.6 %	1.0	364	1.0	\$95	11	12.4 %	1.4	105	1.4	\$282	34	38.2 %	338	0.9	\$81	
Female	25	51.0	1.0	237	1.0	86	6	12.2	1.0	49	1.0	540	20	40.8	217	0.8	84	
Disabled	19	51.4	1.2	173	1.2	93	4	10.8	1.3	36	1.3	724	17	45.9	191	0.8	93	
64 or younger	19	52.8	1.2	173	1.2	93	4	11.1	1.3	36	1.3	724	17	47.2	191	0.8	93	
65-74	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
75-84	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
85 and older	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
Other Eligibles	6	50.0	0.6	64	0.6	69	2	16.7	0.2	13	0.2	31	3	25.0	26	0.7	18	
64 or younger	0	0.0	0	0	0.0	0	1	100.0	0.5	2	0.5	177	1	100.0	2	1.0	14	
65-74	4	50.0	0.4	46	0.4	48	0	0.0	0	0	0.0	0	2	25.0	24	0.6	18	
75-84	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
85 and older	2	66.7	0.9	18	0.9	122	1	33.3	0.1	11	0.1	4	0	0.0	0	0.0	0	
Male	12	30.0	1.0	127	1.0	110	5	12.5	1.8	56	1.8	55	14	35.0	121	1.1	75	
Disabled	11	35.5	1.0	115	1.0	109	5	16.1	1.8	56	1.8	55	11	35.5	91	1.1	85	
64 or younger	10	35.7	1.0	103	1.0	109	3	10.7	1.1	32	1.1	53	10	35.7	79	1.1	95	
65-74	1	33.3	0.9	12	0.9	111	2	66.7	2.6	24	2.6	58	1	33.3	12	0.9	23	
75-84	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
85 and older	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
Other Eligibles	1	11.1	0.9	12	0.9	120	0	0.0	0	0	0.0	0	3	33.3	30	1.3	44	
64 or younger	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
65-74	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	2	100.0	18	1.4	58	
75-84	1	33.3	0.9	12	0.9	120	0	0.0	0	0	0.0	0	1	33.3	12	1.0	23	
85 and older	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	
Unknown	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0	

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 67 beneficiaries who were in nursing facilities for part of their enrollment and their 646 benefit months were excluded from the analysis.
 - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	ANALGESICS - Narcotic					DERMATOLOGICAL					ANALGESICS - ANTI-INFLAMMATORY				
	Users as %					Users as %					Users as %				
	No. of Users	No. of Bene NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	No. of Bene NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	No. of Bene NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	49	55.1 %	457	0.6	\$45	58	65.2 %	619	0.3	\$27	20	22.5 %	204	0.7	\$84
Female	28	57.1	263	0.6	53	26	53.1	293	0.3	39	15	30.6	157	0.6	92
Disabled	20	54.1	195	0.7	70	19	51.4	215	0.3	52	12	32.4	123	0.7	107
64 or younger	17	47.2	159	0.8	85	18	50.0	203	0.3	55	12	33.3	123	0.7	107
65-74	3	300.0	36	0.2	2	1	100.0	12	0.3	3	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	8	66.7	68	0.3	5	7	58.3	78	0.2	4	3	25.0	34	0.4	39
64 or younger	2	200.0	4	1.0	23	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	3	37.5	36	0.3	4	4	50.0	44	0.4	4	3	37.5	34	0.4	39
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	3	100.0	28	0.3	4	3	100.0	34	0.1	3	0	0.0	0	0.0	0
Male	21	52.5	194	0.5	34	32	80.0	326	0.4	16	5	12.5	47	1.0	58
Disabled	16	51.6	153	0.5	37	24	77.4	254	0.4	9	4	12.9	35	1.2	76
64 or younger	15	53.6	141	0.5	40	21	75.0	218	0.3	8	3	10.7	23	1.3	87
65-74	1	33.3	12	0.2	2	3	100.0	36	0.7	17	1	33.3	12	1.0	55
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	5	55.6	41	0.5	21	8	88.9	72	0.4	40	1	11.1	12	0.3	4
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	1	50.0	12	0.1	1	4	200.0	36	0.3	66	1	50.0	12	0.3	4
75-84	1	33.3	12	0.5	7	4	133.3	36	0.4	13	0	0.0	0	0.0	0
85 and older	3	100.0	17	0.9	46	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 67 beneficiaries who were in nursing facilities for part of their enrollment and their 646 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	ANTIDIABETIC				ANTIHYPERTENSIVE				Mean Rx \$	All-Year NF Residents	Bene Mos among All-Year NF Residents	
	Users as %		No. of Bene		Users as %		No. of Bene					
	No. of Users	Residents	Users	Mos among Users	Residents	NF Residents	Users	Mos among Users				
All	34	38.2 %	342	0.8	0.8	35	39.3 %	337	1.0	1.0	89	816
Female	16	32.7	171	0.6	0.6	19	38.8	209	1.0	1.0	49	478
Disabled	10	27.0	104	0.8	0.8	13	35.1	146	1.1	1.1	37	355
64 or younger	9	25.0	92	0.9	0.9	12	33.3	134	1.1	1.1	36	343
65-74	1	100.0	12	0.2	0.2	1	100.0	12	0.7	0.7	1	12
75-84	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0
85 and older	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0
Other Eligibles	6	50.0	67	0.3	1.1	6	50.0	63	0.7	2.3	12	123
64 or younger	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	1	2
65-74	3	37.5	34	0.5	1.8	4	50.0	46	0.6	2.0	8	92
75-84	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0
85 and older	3	100.0	33	0.2	4	2	66.7	17	0.9	3.1	3	29
Male	18	45.0	171	0.9	5.8	16	40.0	128	1.0	5.2	40	338
Disabled	18	58.1	171	0.9	5.8	14	45.2	110	1.0	5.5	31	272
64 or younger	14	50.0	123	0.9	5.7	12	42.9	86	0.9	4.9	28	236
65-74	4	133.3	48	1.0	6.0	2	66.7	24	1.3	7.8	3	36
75-84	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0
85 and older	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0
Other Eligibles	0	0.0	0	0.0	0.0	2	22.2	18	0.9	3.4	9	66
64 or younger	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	1	1
65-74	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	2	21
75-84	0	0.0	0	0.0	0.0	2	66.7	18	0.9	3.4	3	30
85 and older	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	3	14
Unknown	0	0.0	0	0.0	0.0	0	0.0	0	0.0	0.0	0	0

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 67 beneficiaries who were in nursing facilities for part of their enrollment and their 646 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS
 BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALASKA, 2001

Beneficiary Characteristics	No. of Benes with at Least One Part D Excl Rx	% Benes with at Least One Part D Excl Rx	No. of Part D		Total No. Part D Excl Rx	Total Part D Excl Rx \$	\$ per Part D Excl Rx	Part D Excl Rx \$ as % of All Rx \$	Total No. of Benes
			Excl Rx	Bene					
All	13,463	12.5 %	0.4	43,786	\$11	\$1,190,046	\$27	3.2 %	107,802
Age									
5 and younger	3,901	13.4	0.2	6,578	5	136,807	21	5.5	29,155
6-14	1,826	5.2	0.1	3,553	7	240,780	68	3.8	35,083
15-20	1,495	9.1	0.2	3,387	7	116,967	35	3.2	16,362
21-44	4,447	20.8	0.8	17,496	20	418,435	24	3.1	21,357
45-64	1,633	31.4	2.2	11,563	50	258,723	22	2.5	5,202
65-74	103	25.9	1.7	675	22	8,865	13	1.8	397
75-84	36	19.0	2.1	406	39	7,322	18	3.5	189
85 and older	22	39.3	2.3	128	38	2,147	17	2.7	56
Unknown	0	0.0	0.0	0	0	0	0	0.0	1
Basis of Eligibility^c									
Aged	140	24.3	2.0	1,136	29	16,909	15	2.4	577
Disabled	2,406	35.0	2.7	18,309	97	666,014	36	3.5	6,867
Adults	4,515	18.8	0.6	13,745	10	236,056	17	2.7	23,981
Children	6,395	8.4	0.1	10,583	4	270,817	26	3.2	76,351
Unknown	7	26.9	0.5	13	10	250	19	0.5	26
Gender									
Female	8,881	14.9	0.5	30,175	12	735,788	24	3.4	59,691
Male	4,581	9.5	0.3	13,610	9	454,254	33	2.9	48,108
Unknown	1	33.3	0.3	1	1	4	4	0.0	3
Race									
White	5,520	12.2	0.5	23,909	17	751,572	31	3.3	45,413
African American	584	10.2	0.3	1,678	6	35,283	21	1.8	5,743
Other/unknown	7,359	13.0	0.3	18,199	7	403,191	22	3.1	56,646
Use of Nursing Facilities^d									
Entire year	60	67.4	5.2	461	149	13,278	29	3.5	89
Part year	47	70.1	7.2	482	188	12,600	26	3.7	67
None	13,356	12.4	0.4	42,843	11	1,164,168	27	3.2	107,646
Maintenance Assistance Status									
Cash	7,078	16.5	0.7	31,816	20	865,233	27	3.1	42,954
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0
Poverty related	5,279	9.3	0.2	8,834	4	213,128	24	3.5	56,885
Other/unknown	1,106	13.9	0.4	3,136	14	111,685	36	3.6	7,963

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001.
- b. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS PER BENEFIT MONTH
 BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALASKA, 2001

Beneficiary Characteristics	No. Rx per Bene Mo.	Rx \$ per Bene Mo.	\$ per Rx	Barbiturate \$ per Bene Mo.	Benzodiazepine \$ per Bene Mo.	No. of Bene Mos
All	0.0	\$1	\$27	\$0	\$0	900,492
Age						
5 and younger	0.0	1	21	0	0	241,668
6-14	0.0	1	68	0	0	317,107
15-20	0.0	1	35	0	0	131,794
21-44	0.1	3	24	0	1	156,009
45-64	0.2	5	22	0	2	47,477
65-74	0.2	2	13	0	0	4,102
75-84	0.2	4	18	0	1	1,840
85 and older	0.3	4	17	0	1	493
Unknown	0.0	0	0	0	0	2
Basis of Eligibility^c						
Aged	0.2	3	15	0	1	5,735
Disabled	0.3	10	36	0	4	69,806
Adults	0.1	1	17	0	1	168,669
Children	0.0	0	26	0	0	656,177
Unknown	0.1	2	19	0	1	105
Gender						
Female	0.1	1	24	0	0	490,777
Male	0.0	1	33	0	0	409,693
Unknown	0.0	0	4	0	0	22
Race						
White	0.1	2	31	0	1	376,191
African American	0.0	1	21	0	0	49,203
Other/unknown	0.0	1	22	0	0	475,098
Use of Nursing Facilities^d						
Entire year	0.6	16	29	0	8	816
Part year	0.7	20	26	0	9	646
None	0.0	1	27	0	0	899,030
Maintenance Assistance Status						
Cash	0.1	2	27	0	1	373,981
Medically needy	0.0	0	0	0	0	0
Poverty related	0.0	0	24	0	0	456,397
Other/unknown	0.0	2	36	0	1	70,114

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001.
- b. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
 ALASKA, 2001

Drug Category	No. Users	Rx \$ per User	Total Rx \$	Rx \$ as % of All Part D Excl Rx \$	Total No. Rx.	\$ per Rx	No. Rx as % of All Part D Excl Rx
All	15,090	\$79	\$1,190,046	100.0 %	43,786	\$27	100.0 %
Anorexia or weight loss/gain	357	55	19,717	1.7	481	41	1.1
Fertility drugs	9	64	579	0.0	9	64	0.0
Drugs for cosmetic purposes	102	507	51,703	4.3	412	125	0.9
Cough and cold medications	1,486	152	225,973	19.0	2,825	80	6.5
Vitamins and minerals	2,067	135	279,679	23.5	6,568	43	15.0
Non-prescription drugs	5,049	36	183,746	15.4	10,852	17	24.8
Barbiturates	236	53	12,524	1.1	1,063	12	2.4
Benzodiazepines	3,358	108	362,032	30.4	18,037	20	41.2
Other Part D Excl Rx Drugs	2,426	22	54,093	4.5	3,539	15	8.1

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2001. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility, those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, ALASKA, 2001

Beneficiary Characteristics	No. of Beneficiaries					No. of Beneficiaries by Age Group					
	All	Aged	Disabled	Adults	Children	All	Aged	Disabled	Adults	Children	Unknown
All	107,802	577	6,867	23,981	76,351	900,492	5,735	69,806	168,669	656,177	105
Age											
5 and younger	29,155	0	356	0	28,799	241,668	0	3,267	0	238,401	0
6-14	35,083	0	717	4	34,362	317,107	0	7,844	24	309,239	0
15-20	16,362	0	562	2,743	13,055	131,794	0	5,703	18,206	107,880	5
21-44	21,357	0	2,369	18,840	135	156,009	0	24,452	130,851	657	49
45-64	5,202	8	2,796	2,387	0	47,477	71	27,824	19,531	0	51
65-74	397	326	65	6	0	4,102	3,346	701	55	0	0
75-84	189	188	1	0	0	1,840	1,837	3	0	0	0
85 and older	56	55	1	0	0	493	481	12	0	0	0
Unknown	1	0	0	1	0	2	0	0	2	0	0
Gender											
Female	59,691	370	3,549	18,475	37,271	490,777	3,757	36,660	128,805	321,450	105
Male	48,108	207	3,318	5,506	39,077	409,693	1,978	33,146	39,864	334,705	0
Unknown	3	0	0	0	3	22	0	0	0	22	0
Race											
White	45,413	108	3,711	10,956	30,614	376,191	1,014	37,828	75,942	261,310	97
African American	5,743	6	425	1,234	4,078	49,203	53	4,239	9,063	35,848	0
Other/unknown	56,646	463	2,731	11,791	41,659	475,098	4,668	27,739	83,664	359,019	8
Use of Nursing Facilities^c											
Entire year	89	20	68	0	1	816	187	627	0	2	0
Part year	67	10	57	0	0	646	84	562	0	0	0
None	107,646	547	6,742	23,981	76,350	899,030	5,464	68,617	168,669	656,175	105
Maintenance Assistance Status											
Cash	42,954	550	6,278	15,844	20,282	373,981	5,521	63,748	123,076	181,636	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0
Poverty related	56,885	0	0	6,310	50,549	456,397	0	0	31,642	424,650	105
Other/unknown	7,963	27	589	1,827	5,520	70,114	214	6,058	13,951	49,891	0
Managed Care Status											
FFS all year	107,802	577	6,867	23,981	76,351	900,492	5,735	69,806	168,669	656,177	105
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, ALASKA, 2001

	Bene Mos in Cell J of Table 1		Bene Mos and		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos
All	107,802	900,492	107,802	900,492	107,802	900,492	0	0
FFS all year	107,802	900,492	107,802	900,492	107,802	900,492	0	0
FFS part year, with Rx claims	0	0	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2001 file for Alaska, released by CMS in 06/2005. This table was produced on 09/19/2006.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.